the core of our corporate values
Zylox-Tonbridge Medical Technology Co., Ltd. (2190.HK, "the Company" ), one of the leading players in the neuro- and peripheral-vascular interventional medical device market in China, announ...
On December 2nd, 2022, Zylox-Tonbridge (2190.HK, “the Company”) announced that the company was granted marketing approval by China’s National Medical Products Administration (NMPA) for its self-dev...
On August 15, Zylox-Tonbridge (2190.HK, “the Company”) released its 2022 interim results.
Chinese channal:https://live.hh-medic.com/liveview/1251English channal:https://live.hh-medic.com/liveview/1252
On April12, Zylox-Tonbridge (2190.HK, “the Company”) announced its PTA Balloon Catheter-Large Diameter, a product independently developed by the Company, has been granted the marketing approval by t...
Zylox-Tonbridge (2190.HK, hereinafter called the Company) announced on March 15 its first fiscal-year financial report since its IPO on Hong Kong Stock Exchange.The Company reported an ope...